[go: up one dir, main page]

PE20020572A1 - Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos - Google Patents

Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos

Info

Publication number
PE20020572A1
PE20020572A1 PE2001001202A PE2001001202A PE20020572A1 PE 20020572 A1 PE20020572 A1 PE 20020572A1 PE 2001001202 A PE2001001202 A PE 2001001202A PE 2001001202 A PE2001001202 A PE 2001001202A PE 20020572 A1 PE20020572 A1 PE 20020572A1
Authority
PE
Peru
Prior art keywords
antigens
compositions
istimation
chemicione
cytocine
Prior art date
Application number
PE2001001202A
Other languages
English (en)
Inventor
Molina Luis Enrique Fernandez
Ramirez Belinda Sanchez
Pestana Eduardo Raul Suarez
La Barrera Aira Anabel De
Pardillo Circe Mesa
Leon Delgado Joel De
Rodriguez Yildian Diaz
Rodriguez Rolando Perez
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CU20000285A external-priority patent/CU23000A1/es
Priority claimed from CU20010167A external-priority patent/CU23009A1/es
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of PE20020572A1 publication Critical patent/PE20020572A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE A UNA COMPOSICION INMUNOGENICA QUE COMPRENDE: a) UNO O MAS ANTIGENOS INMUNOGENICOS; b) UN VEHICULO QUE CONSISTE EN PROTEOLIPOSOMAS DERIVADOS DEL COMPLEJO DE PROTEINAS DE LA MEMBRANA EXTERNA DE UNA BACTERIA GRAM-NEGATIVA (NEISSERIA MENINGITIDIS) LOS CUALES CONTIENEN GANGLIOSIDOS INCORPORADOS Y c) ADYUVANTES. LOS ANTIGENOS PUEDEN SER PEPTIDOS, POLIPEPTIDOS, PROTEINAS, SUS CORRESPONDIENTES SECUENCIAS DE ADN, CELULAS O SUS LISADOS Y PROTEOLIPOSOMAS (VSSP) FORMADOS AL UNIR EL COMPLEJO DE PROTEINAS DE LA MEMBRANA EXTERNA (CPME) DE NEISSERIA MENINGITIDIS CON GANGLIOSIDOS MEDIANTE ENLACES HIDROFOBOS. ESTAS COMPOSICIONES PUEDEN FORMULARSE SOLAS O FORMANDO EMULSIONES CON EL ADYUVANTE DE NATURALEZA OLEOSA SELECCIONADO DE UN POLIPEPTIDO NATURAL O RECOMBINANTE O EL ADYUVANTE INCOMPLETO DE FREUND (AIF), UNA CITOCINA O UNA QUIMICIONA DONDE LA CITOCINA ES EL FACTOR DE ESTIMULACION DE COLONIAS DE GRANULOCITOS Y MACROFAGOS. LAS COMPOSICIONES PERMITEN HACER ANTIGENOS DE MUY BAJA INMUNOGENICIDAD, TALES COMO RECEPTORES DE FACTORES DE CRECIMIENTO SIN NECESIDAD DE RECURRIR A CAMBIOS ESTRUCTURALES EN LOS MISMOS. EN PARTICULAR MUESTRA COMO PREPARAR COMPOSICIONES INMUNOESTIMULADORAS CAPACES DE GENERAR RESPUESTAS INMUNES ESPECIFICAS INCLUSO EN HUESPEDES INMUNOCOMPROMOMETIDOS COMO LOS QUE PADECEN DE CANCER E INFECCIONES DE ORIGEN VIRAL O BACTERIANAS
PE2001001202A 2000-12-06 2001-11-29 Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos PE20020572A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20000285A CU23000A1 (es) 2000-12-06 2000-12-06 Composiciones vacunales para la inmunoterapia activa específica del cáncer
CU20010167A CU23009A1 (es) 2001-07-12 2001-07-12 Preparaciones para potenciar la inmunogenicidad depreparaciones para potenciar la inmunogenicidad de antígenos poco inmunogénicos antígenos poco inmunogénicos

Publications (1)

Publication Number Publication Date
PE20020572A1 true PE20020572A1 (es) 2002-07-31

Family

ID=38812545

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001001202A PE20020572A1 (es) 2000-12-06 2001-11-29 Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos

Country Status (19)

Country Link
US (1) US7776342B2 (es)
EP (1) EP1356822B1 (es)
JP (1) JP4210519B2 (es)
KR (1) KR100850473B1 (es)
CN (1) CN1291755C (es)
AR (1) AR031638A1 (es)
AT (1) ATE485833T1 (es)
AU (2) AU2002221519B2 (es)
BR (1) BRPI0116013B8 (es)
CA (1) CA2431188C (es)
DE (1) DE60143363D1 (es)
DK (1) DK1356822T3 (es)
EA (1) EA005138B1 (es)
MX (1) MXPA03005032A (es)
NZ (1) NZ526282A (es)
PE (1) PE20020572A1 (es)
UY (1) UY27059A1 (es)
WO (1) WO2002045746A2 (es)
ZA (1) ZA200304411B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1367395A1 (de) * 2002-05-02 2003-12-03 B.R.A.H.M.S Aktiengesellschaft Diagnose von Neoplasmen mit Hilfe von anti-Gangliosid-Antikörpern
EP1358910A1 (de) * 2002-05-02 2003-11-05 B.R.A.H.M.S Aktiengesellschaft Verfahren und Mittel zur Prävention, Hemmung und Therapie von Krebserkrankungen
CU23257A1 (es) * 2003-02-27 2008-01-24 Centro Inmunologia Molecular COMPOSICIONES VACUNALES A BASE DE GANGLIOSIDOS PARA LA ADMINISTRACION SUBCUTáNEA
AR045815A1 (es) * 2003-10-09 2005-11-16 Ct Ingenieria Genetica Biotech Composiciones farmaceuticas que contienen antigenos del virus de papiloma humano
US8147840B2 (en) * 2004-05-14 2012-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human immunodeficiency virus (HIV) immunization strategies employing conformationally-stabilized, surface-occluded peptides comprising a gp41 2F5 epitope in association with lipid
WO2010003219A1 (en) * 2008-06-17 2010-01-14 Universite Laval Compositions comprising salmonella porins and uses thereof as adjuvants and vaccines
BR112013016231B1 (pt) * 2010-12-22 2021-03-23 Bayer Intellectual Property Gmbh Composição imunomoduladora para o tratamento de doença respiratória bovina
KR101323845B1 (ko) * 2011-01-21 2013-10-31 광주과학기술원 외막소포체를 유효성분으로 포함하는 항암용 약제학적 조성물
CU24070B1 (es) * 2011-12-27 2015-01-29 Ct De Inmunología Molecular Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
EP2970409A2 (en) * 2013-03-15 2016-01-20 Bioven 3 Limited Self-assembling synthetic proteins
CU24299B1 (es) * 2013-08-02 2017-12-08 Centro De Inmunología Molecular Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico
HK1194912A2 (en) * 2013-09-17 2014-10-24 Bestop Group Holdings Ltd Growth factor concentrate and the use thereof
US10105306B2 (en) * 2013-09-17 2018-10-23 Bestop Group Holdings Limited Method of preparing a growth factor concentrate
EP3116893B1 (en) * 2014-03-11 2019-08-28 Jacques Fantini A chimeric peptide that interacts with cell membrane gangliosides
WO2018166542A1 (es) 2017-03-15 2018-09-20 Centro De Inmunologia Molecular Método para el tratamiento de pacientes con carcinomas
US12019073B2 (en) * 2017-03-15 2024-06-25 Centro De Inmunologia Molecular Method for the treatment of patients with carcinomas
EP3688026A4 (en) * 2017-09-27 2021-11-10 L2 Diagnostics, LLC PHARMACEUTICAL AND VACCINAL COMPOSITIONS BASED ON PEPTIDE ERBB AND THEIR THERAPEUTIC USES FOR THE TREATMENT OF CANCER
CU24534B1 (es) * 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3
CU20170173A7 (es) * 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras
CN109865137A (zh) * 2019-01-23 2019-06-11 天德悦（北京）生物科技有限责任公司 经碘代乙酰基活化的琼脂糖微球在提高多肽或蛋白类免疫原免疫原性中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857637A (en) * 1986-05-07 1989-08-15 Genentech, Inc. Methods and compositions for immunologically modulating growth hormone receptor activity
IT1206250B (it) * 1987-02-18 1989-04-14 Ist Farmacoterapico It Spa Stiche umane e relativi prodotti metodo per l'estrazione di antigeni di membrana aventi proprieta' immunogene a partire da cellule neopla-
US5726292A (en) * 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
AU4662393A (en) 1992-07-08 1994-01-31 Schering Corporation Use of gm-csf as a vaccine adjuvant
DE69428763T2 (de) * 1993-12-09 2002-08-01 Centro De Inmunologia Molecular, Ciudad De La Habana Monoklonale Antikörper gegen Ganglioside und deren Verwendung in der spezifischen, aktiven Immuntherapie gegen bösartige Tumoren
CU22420A1 (es) * 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
EP1045698B1 (en) * 1998-01-16 2006-06-07 Biomira Usa Inc. Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes

Also Published As

Publication number Publication date
US7776342B2 (en) 2010-08-17
WO2002045746A3 (es) 2002-12-27
UY27059A1 (es) 2002-04-26
DK1356822T3 (da) 2011-02-07
MXPA03005032A (es) 2004-09-10
EA005138B1 (ru) 2004-12-30
BR0116013A (pt) 2004-01-06
CA2431188C (en) 2010-09-07
EP1356822B1 (en) 2010-10-27
NZ526282A (en) 2005-01-28
ZA200304411B (en) 2004-07-29
ATE485833T1 (de) 2010-11-15
US20020136735A1 (en) 2002-09-26
KR20030061838A (ko) 2003-07-22
EA200300640A1 (ru) 2003-12-25
CN1484532A (zh) 2004-03-24
KR100850473B1 (ko) 2008-08-07
AU2002221519B2 (en) 2006-11-23
CA2431188A1 (en) 2002-06-13
JP4210519B2 (ja) 2009-01-21
DE60143363D1 (de) 2010-12-09
AU2151902A (en) 2002-06-18
CN1291755C (zh) 2006-12-27
BRPI0116013B1 (pt) 2018-07-24
BRPI0116013B8 (pt) 2021-05-25
EP1356822A2 (en) 2003-10-29
JP2004523494A (ja) 2004-08-05
WO2002045746A2 (es) 2002-06-13
AR031638A1 (es) 2003-09-24
HK1063726A1 (en) 2005-01-14

Similar Documents

Publication Publication Date Title
PE20020572A1 (es) Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
AR075047A1 (es) Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga. polipeptido purificado. anticuerpo ant-stx2. kit.
CY1112105T1 (el) Ανοσογονα βακτηριακα κυστιδια με πρωτεϊνες εξωτερικης μεμβρανης
UY25877A1 (es) Antígenos estreptococo
EP1801219A3 (en) Neisserial antigenic peptides
ATE522541T1 (de) Bakterielle adhäsine konformere
EA200901060A1 (ru) Новый способ и композиции
RU2010138815A (ru) МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP
RU2020113032A (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
EA201391467A1 (ru) Липосомные композиции
WO2021239838A3 (en) Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes
NO20062044L (no) Piscirickettsia salmonis-antigener og anvendelse derav
PE20241621A1 (es) Composiciones de polinucleotidos y sus usos
Marshall et al. Immunological characterization of a bacterial protein isolated from salmonid fish naturally infected with Piscirickettsia salmonis
MX2025010274A (es) Composiciones para su uso en el tratamiento de clamidia
WO2023038961A3 (en) Common cold coronavirus t cell epitopes, methods and uses thereof
DE602005018615D1 (de) Schen polypeptiden und deren verwendung als impfstoffe und in der immuntherapie
US10918707B2 (en) VirB10 for vaccination against gram negative bacteria
ATE493146T1 (de) Igf-1 als impfstoffhilfsmittel für katzen, insbesondere gegen feline retroviren
PE20010239A1 (es) Gen derivado de lawsonia y polipeptidos, peptidos y proteinas de hemolisina relacionados y sus usos
CU23009A1 (es) Preparaciones para potenciar la inmunogenicidad depreparaciones para potenciar la inmunogenicidad de antígenos poco inmunogénicos antígenos poco inmunogénicos
AR030292A1 (es) Una proteina gapc; su metodo de produccion y su uso; un polinucleotido aislado y su uso; un vector recombinante; una celula huesped; una composicion de vacuna y su metodo de produccion; anticuerpos y sus usos; y un kit de inmunodiagnostico
Boesch et al. Localization of the vacuolar-type ATPase in swimbladder gas gland cells of the European eel (Anguilla anguilla)
RU2013115434A (ru) Пептиды ttll4 и содержащие их вакцины
BRPI0100837B8 (pt) sequência de dna que codifica a proteína externa de membrana antigênica e específica de salmonella typhi

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed